HTB homepage • Conference reports • Articles by subject • Subscribe March 2016 Contents Editorial March/April 2016: Volume 17 Number 3/4 Conference reports 23rd Conference on Retroviruses and Opportunistic Infections (CROI 2016), 22-25 February 2016, Boston Dual long-acting injections of cabotegravir plus rilpivirine: 32-week results from LATTE-2 study New NRTI MK-8591 (EFdA): weekly oral dosing and once-yearly slow-release dosing has potential for HIV treatment and PrEP Similar viral load reductions at week 4 when dolutegravir is used with 2- or 3-drug initial ART 48-week results for NNRTI doravirine compared to efavirenz Dramatic increase in use of oral TDF/FTC for PrEP in the US – plus a few cautions Future oral and long-acting formulations for PrEP: pills, films, gels, injections and depots First data on TAF as PrEP to prevent HIV infection Long-acting cabotegravir as PrEP protects macaques against IV exposure but will need two-monthly injections Role for maraviroc as HIV PrEP likely to need dual combinations Dapivirine PrEP vaginal ring shows only limited PrEP protection against HIV in African women Early data from dolutegravir use during pregnancy Dolutegravir: 48 week results in children age 6 to 12 years old New antiretrovirals could mean savings up to US $3 billion by 2025 Countries with lower HIV prevalence have lower ART coverage Nigerian herbal medicines widely used by HIV positive people can contain antiretrovirals Cure research news from CROI 2016 Antiretrovirals EU adopts positive opinion on dual formulation of F/TAF New TAF-containing fixed dose combination approved in the US Treatment access Community oppose dolutegravir and cabotegravir patents in India MSF call for cap for MDR-TB drug costs: only 180 people use delamanid over two years Global Fund provides Uganda with a year of drugs to meet shortages Transgender people left behind in the fight against HIV: Only 17 out of 130 countries have transgender representatives Mbeki shows no remorse for role in AIDS deaths Side effects Alcohol risks are higher in HIV positive people and linked to increased mortality HIV prevention and transmission Canada approves TDF/FTC as PrEP NHS England pulls proposed timeline for PrEP: perpetuates HIV health crisis in gay men and trans people UK community campaign calls for NHS England to be accountable for PrEP timeline Other news HIV positive transplant donors approved in the US PDFs March/April 2016: Volume 17 Number 3/4 HTB homepage • Conference reports • Articles by subject • Subscribe
